Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Phase 2

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
Other: Placebo

Registration Number: NCT05468736

Lead Sponsor: Novavax

Brief Summary: This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart and NVX CoV2373 or a variant-based vaccine given as a booster dose or at crossover in pediatric participants (3 age cohorts; 6 to \< 12 years, 2 to \< 6 years, and 6 to \< 24 months of age). Each age cohort will be conducted in 2 parts starting with the oldest age cohort (6 to \< 12 years of age).

Detailed Description: This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart and NVX CoV2373 or a variant-based vaccine given as a booster dose or at crossover in pediatric participants (3 age cohorts; 6 to \< 12 years, 2 to \< 6 years, and 6 to \< 24 months of age).

Each age cohort will be conducted in 2 parts starting with the oldest age cohort (6 to \< 12 years of age).

Part 1 will enroll approximately 120 healthy or medically stable sentinel participants per age cohort (10% of the intended enrollment population per age cohort, for a total of 360 sentinel participants overall) who will be randomized in a 1:1 ratio to receive 2 doses of NVX-CoV2373 or placebo with doses given 21 days apart.

Part 2 will enroll a larger number of healthy or medically stable participants (N= approximately 1,080 per age cohort), for a total of approximately 3,240 pediatric participants enrolled in Part 2, and a total of approximately 3,600 participants enrolled in the entire trial). Initial randomization in Part 2 will be in a 2:1 ratio, and the safety and effectiveness of 2 doses of NVX-CoV2373 given 21 days apart will be assessed.

Recruitment & Eligibility

Status: ACTIVE_NOT_RECRUITING

Sex: All

Target Recruitment: 3600

Inclusion Criteria

To be included in this study, each individual must satisfy all of the following criteria:

Pediatric participants 6 months to < 12 years of age at randomization, determined to be healthy or medically stable by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Vital signs must be within the normal range prior to the first vaccination, according to the child's age, sex, weight, and height/length.
For children from 6 months to < 12 months of age: born at full-term (≥ 37 weeks gestation) with a minimum birth weight of 2.5 kilograms (kg).
Participant and parent(s)/caregiver(s) or legally acceptable representative willing and able to give informed consent and assent, as required, prior to study enrollment and to comply with study procedures.
Participants of childbearing potential (defined as any participant who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through 3 months after the last vaccination OR agree to consistently use a highly effective contraception method from at least 28 days prior to enrollment and through 3 months after the last vaccination.
Agree not to participate in another SARS-CoV-2 prevention trial for the duration of the study.

Exclusion Criteria

If an individual meets any of the following criteria, he or she is ineligible for this study:

Any acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 100.4°F [≥ 38.0°C]). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
Unstable acute or chronic illness. Criteria for unstable medical conditions include:
1. Substantive changes in chronic prescribed medication (change in class or significant change in dose) in the past 2 months.
2. Currently undergoing workup of undiagnosed illness that could lead to a diagnosis of a new condition.
NOTE: Well-controlled human immunodeficiency virus [HIV] infection with undetectable HIV ribonucleic acid [RNA < 50 copies/mL] and CD4 count > 200 cells/µL for at least 1 year, documented within the last 6 months, is NOT considered an unstable chronic illness. Participant's or parent's/caregiver's verbal report will suffice as documentation.
Participation in research involving an investigational product (drug/biologic/device) administered within 45 days prior to the first study vaccination.
History of a previous laboratory-confirmed diagnosis of SARS-CoV-2 infection or COVID-19.
Prior administration of an investigational, authorized, or approved Coronavirus vaccine (ie, against either SARS-CoV, SARS-CoV-2, or MERS CoV) or expected receipt during the period of study follow-up.
Previous or current diagnosis of MIS-C.
Receipt of medications intended to prevent or treat COVID-19.
Received any vaccine within 14 days prior to first study vaccination or planned receipt of any vaccine before Day 49 (ie, 28 days after the second vaccination), except for influenza vaccination, which may be received > 14 days prior to or > 14 days after any study vaccination.
Known or suspected congenital or acquired immunodeficiency or autoimmune disease/condition; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for > 14 continuous days) within 90 days prior to first study vaccination. NOTE: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 20 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are permitted. Stable autoimmune endocrine disorders (eg, thyroiditis, pancreatitis), including stable diabetes mellitus type 1, or participants with a history of Kawasaki disease are NOT excluded.
Received immunoglobulin or blood-derived products within 90 days prior to first study vaccination.
Active cancer (malignancy) on chemotherapy within 1 year prior to first study vaccination (with the exception of malignancy cured via excision, at the discretion of the investigator).
Any known allergies to products contained in the investigational product.
Participants who are breastfeeding a child, pregnant or who plan to become pregnant within 3 months following the last study vaccination.
Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with the evaluation of the trial vaccine or interpretation of study results.
Study team member or first-degree relative of any study team member (inclusive of Sponsor, and study site personnel involved in the study).
Current participation in any other COVID-19 prevention clinical trial.
Participants with a history of myocarditis or pericarditis.

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Cohort-1(6 to < 12 y)-Part-1(Active Vaccine)	SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)	NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
Cohort-1(6 to < 12 y)-Part-1(Placebo)	Placebo	Placebo (normal saline)
Cohort-1(6 to < 12 y)-Part-2(Active Vaccine)	SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)	NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
Cohort-1(6 to < 12 y)-Part-2(Placebo)	Placebo	Placebo (normal saline)
Cohort-2(2 to < 6 y)-Part-1(Active Vaccine)	SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)	NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
Cohort-2(2 to < 6 y)-Part-1(Placebo)	Placebo	Placebo (normal saline)
Cohort-2(2 to < 6 y)-Part-2(Active Vaccine)	SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)	NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
Cohort-2(2 to < 6 y)-Part-2(Placebo)	Placebo	Placebo (normal saline)
Cohort-3(6 to < 24 m)-Part-1(Active Vaccine)	SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)	NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
Cohort-3(6 to < 24 m)-Part-1(Placebo)	Placebo	Placebo (normal saline)
Cohort-3(6 to < 24 m)-Part-2	SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)	NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
Cohort-3(6 to < 24 m)-Part-2(Placebo)	Placebo	Placebo (normal saline)

Primary Outcome Measures

Name	Time	Method
Reactogenicity Incidence and Severity	Day 0 to Day 7	Reactogenicity incidence, duration, and severity (mild, moderate, severe, or potentially life-threatening) recorded by parent(s)/caregiver(s) on an electronic patient-reported outcome diary application (eDiary) on days of vaccination and subsequent 6 days (total 7 days after each vaccine injection).
Incidence and Severity of Adverse Events of Special Interest (AESIs)	Day 0 to Day 730	Incidence and severity of AESIs (including multisystem inflammatory syndrome in children \[MIS-C\], and myocarditis and/or pericarditis) after initial vaccination at Day 0 through Month 24 or the EoS.
Incidence and Severity of Serious Adverse Events (SAEs)	Day 0 to Day 730	Incidence and severity of SAEs after initial vaccination at Day 0 through Month 24 or the EoS.
Incidence and Severity of Unsolicited Adverse Events (AEs)	Day 0 to Day 28	Incidence and severity of unsolicited AEs through 28 days after second injection of each set of vaccinations (initial and crossover), and after a booster dose.
Incidence and Severity of Medically Attended Adverse Events (MAAEs)	Day 0 to Day 28	Incidence and severity of MAAEs through 28 days after second injection of each set of vaccinations (initial and crossover), and after a booster dose.
Incidence and Severity of MAAEs Attributed to Study Vaccine	Day 0 to Day 730	Incidence and severity of MAAEs attributed to study vaccine after initial vaccination at Day 0 through Month 24 or the EoS.
Death due to any cause	Day 0 to Day 730	Death due to any cause occurring from Day 0 to EoS.

Secondary Outcome Measures

Name	Time	Method
Participants with PCR positive mild, moderate or severe COVID-19 after the primary series of 2 doses	Day 0 to Day 730	Incidence rate of participants with first episode of PCR-positive mild, moderate, or severe COVID-19 overall and per age cohort, with or without positive anti-NP serology at baseline after the primary series of 2 doses.
Participants with PCR positive moderate or severe COVID-19 after the primary series of 2 doses	Day 0 to Day 730	Incidence rate of participants with first episode of PCR-positive moderate or severe COVID-19 overall and per age cohort, with or without positive anti-NP serology at baseline, and by risk factors to develop severe COVID-19 after the primary series of 2 doses.
Participants with diagnostic test - positive asymptomatic, mild, moderate or severe COVID-19 after the primary series of 2 doses	Day 0 to Day 730	Incidence rate of participants with first episode of diagnostic test-positive asymptomatic, mild, moderate, or severe COVID-19 (regardless of confirmatory test used, ie, PCR or rapid antigen test, and of testing location, ie, central or externally tested) overall and per age cohort, with or without positive anti-NP serology at baseline after the primary series of 2 doses.
Participants with diagnostic test - positive moderate or severe COVID-19 after the primary series of 2 doses	Day 0 to Day 730	Incidence rate of participants with first episode of diagnostic test-positive moderate or severe COVID-19 (regardless of confirmatory test used, ie, PCR or rapid antigen test, and of testing location, ie, central or externally tested) overall and per age cohort, with or without positive anti NP serology at baseline, and by risk factors to develop severe COVID-19 after the primary series of 2 doses.
Participants with PCR positive mild, moderate or severe COVID-19 after the booster dose	Day 0 to Day 730	Incidence rate of participants with first episode of PCR-positive mild, moderate, or severe COVID-19 overall and per age cohort, with or without positive anti-NP serology at baseline after the booster dose.
Participants with PCR positive moderate or severe COVID-19 after the booster dose	Day 0 to Day 730	Incidence rate of participants with first episode of PCR-positive moderate or severe COVID-19 overall and per age cohort, with or without positive anti-NP serology at baseline, and by risk factors to develop severe COVID-19 after the booster dose.
Participants with diagnostic test - positive asymptomatic, mild, moderate or severe COVID-19 after the booster dose	Day 0 to Day 730	Incidence rate of participants with first episode of diagnostic test-positive asymptomatic, mild, moderate, or severe COVID-19 (regardless of confirmatory test used, ie, PCR or rapid antigen test, and of testing location, ie, central or externally tested) overall and per age cohort, with or without positive anti-NP serology at baseline after the booster dose.
Participants with diagnostic test moderate or severe COVID-19 after the booster dose	Day 0 to Day 730	Incidence rate of participants with first episode of diagnostic test-positive moderate or severe COVID-19 (regardless of confirmatory test used, ie, PCR or rapid antigen test, and of testing location, ie, central or externally tested) overall and per age cohort, with or without positive anti-NP serology at baseline after the booster dose, and by risk factors to develop severe COVID-19.
Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specified Time Points	Day 0 to Day 730	Antibodies to SARS-CoV-2 NP, regardless of whether the infection was symptomatic. Antibodies to SARS-CoV-2 NP at Days 0 and 35, at Crossover Visit 1, at Booster vaccination visit, and at Months 12 and 24 will be used to determine natural infection and to determine the incidence of asymptomatic infection acquired during study follow-up.
Neutralizing antibody response, post-booster, by age cohort,seronegative to anti-SARS-CoV-2 NP antibodies at baseline and pre-booster	Day 0 to Day 28	Neutralizing antibody response at 28 days post booster for pediatric participants in the Immunogenicity Population overall and by age cohort, seronegative to anti-SARS-CoV-2 NP antibodies at baseline and pre-booster, compared with that observed at 28 days post-booster vaccination in young adult participants 18 to \< 26 years of age.
Neutralizing antibody response, by age cohort, regardless of serostatus at baseline and pre-booster	Day 0 to Day 28	Neutralizing antibody response at 28 days post-booster for pediatric participants in the Immunogenicity Population overall and by age cohort, regardless of serostatus at baseline and pre-booster, compared with that observed in pediatric participants at baseline (Day 0).
Serum IgG levels to SARS-CoV-2 S protein, post-booster, by age cohort, regardless of serostatus at baseline and pre-booster vaccination	Day 0 to Day 28	Serum IgG levels to SARS-CoV-2 S protein at 28 days post-booster vaccination for pediatric participants in the Immunogenicity Population overall and by age cohort, regardless of serostatus at baseline and pre-booster vaccination, compared with that observed at 28 days post-booster vaccination in young adult participants 18 to \< 26 years of age.
Serum IgG levels to SARS-CoV-2 S protein, post booster, by age cohort, regardless of serostatus at baseline and pre-booster	Day 0 to Day 28	Serum IgG levels to SARS-CoV-2 S protein at 28 days post-booster for pediatric participants in the Immunogenicity Population overall and by age cohort, regardless of serostatus at baseline and pre-booster, compared with that observed in pediatric participants at baseline (Day 0).
Serum IgG levels to SARS-CoV-2 S protein , post booster, by age cohort, regardless of serostatus at baseline and pre-booster	Day 0 to Day 35	Serum IgG levels to SARS-CoV-2 S protein at 28 days post-booster for pediatric participants in the Immunogenicity Population overall and by age cohort, regardless of serostatus at baseline and pre-booster, compared with that observed in pediatric participants at Day 35,
Neutralizing antibody response for pediatric participants and adult participants expressed as Geometric Mean Titers (GMT)	Day 35	Neutralizing antibody response for pediatric participants compared with adult participants 18 to \< 26 years of age from the Adult Main Study at Day 35
Neutralizing antibody response for pediatric participants and adult participants expressed as Sero response (SRR)	Day 35	Neutralizing antibody response for pediatric participants compared with adult participants 18 to \< 26 years of age from the Adult Main Study at Day 35
Serum IgG levels to SARS-CoV-2 S protein after second injection of the initial vaccination series	Day 35	Serum IgG levels to SARS-CoV-2 S protein 14 days after second injection of the initial vaccination series (Day 35) in pediatric participants in the Immunogenicity Population by age cohort and subsets with and without anti-NP antibodies at baseline.
Treatment and severity of COVID 19 after a PCR-confirmed case	Day 0 to Day 730	Description of course, treatment and severity of COVID 19 reported after a PCR-confirmed case via the Case Form.
Antibodies to SARS-CoV-2 NP, regardless of whether the infection was symptomatic.	Day 0 to Day 730	Antibodies to SARS-CoV-2 NP, regardless of whether the infection was symptomatic. Antibodies to SARS-CoV-2 NP at Days 0 and 35, at Crossover Visit 1, at Booster vaccination visit, and at Months 12 and 24 will be used to determine natural infection and to determine the incidence of asymptomatic infection acquired during study follow-up.
Serum IgG levels to SARS-CoV-2 S protein expressed as GMT	Day 180 to Day 730	Serum IgG levels to SARS-CoV-2 S protein at Months 6 (pre- booster), 7/8 (1-month post-booster), 12, and 24 post-vaccination with NVXCoV2373.
MN titers to SARS-CoV-2 S protein expressed as GMT	Day 180 to Day 730	MN titers at Months 6 (pre- booster), 7/8 (1-month post-booster), 12, and 24 post-vaccination with NVXCoV2373.

Trial Locations

Locations (94): Tekton Research Beaumont
🇺🇸
Beaumont, Texas, United States
Research Your Health
🇺🇸
Plano, Texas, United States
Morehouse School of Medicine
🇺🇸
Atlanta, Georgia, United States
Trio Clinical Trials
🇺🇸
Houston, Texas, United States
Velocity Clinical Research - West Jordan
🇺🇸
West Jordan, Utah, United States
Fundacion Centro de Investigacion Clinica - CIC
🇨🇴
Medellin, Antioquia, Colombia
Centro de Atencion e Investigacion Medica - CAIMED
🇨🇴
Yopal, Casanare, Colombia
Clinical Research Institute S.C.
🇲🇽
Tlalnepantla, Mexico
Instituto Dermatologico y Cirugia de Piel Dr. Huberto Bogaert Diaz IDCP
🇩🇴
Santo Domingo, Distrito Nacional, Dominican Republic
Centro de Investigaciones Pediátricas (CIP)
🇬🇹
Guatemala, Guatemala
Innovacion y Desarrollo en Ciencias de la Salud (IDeCSa)
🇲🇽
Tlalpan, Mexico City, Mexico
Panamerican Clinical Research S.A de C.V.
🇲🇽
Guadalajara, Jalisco, Mexico
Panamerican Clinical Research, Mexico S.A de C.V.
🇲🇽
Cuernavaca, Morelos, Mexico
St Georges Hospital
🇬🇧
London, United Kingdom
Cordova Research Institute, LLC
🇺🇸
Miami, Florida, United States
Clinical Research Associates, Inc.
🇺🇸
Nashville, Tennessee, United States
Preferred Research Partners, Inc.
🇺🇸
Little Rock, Arkansas, United States
Advanced Research Center
🇺🇸
Anaheim, California, United States
Orange County Research Institute
🇺🇸
Ontario, California, United States
Coast Clinical Research, LLC
🇺🇸
Bellflower, California, United States
Apex Research Group
🇺🇸
Fair Oaks, California, United States
California Research Foundation
🇺🇸
San Diego, California, United States
Clinical Research of California
🇺🇸
Walnut Creek, California, United States
Imagine Research of Palm Beach County
🇺🇸
Boynton Beach, Florida, United States
Palm Harbor Dermatology PA
🇺🇸
Brandon, Florida, United States
Westside Center for Clinical Research
🇺🇸
Jacksonville, Florida, United States
ARS-Nona Pediatric Center
🇺🇸
Orlando, Florida, United States
Tekton Research - Atlanta
🇺🇸
Chamblee, Georgia, United States
Michael W. Simon, M.D., PSC
🇺🇸
Lexington, Kentucky, United States
Leavitt Clinical Research
🇺🇸
Idaho Falls, Idaho, United States
Bluegrass Clinical Research, Inc./All Children Pediatrics
🇺🇸
Louisville, Kentucky, United States
Velocity Clinical Research - Covington, LA
🇺🇸
Covington, Louisiana, United States
Velocity Clinical Research - Covington
🇺🇸
Covington, Louisiana, United States
Velocity Clinical Research - Lafayette LA
🇺🇸
Lafayette, Louisiana, United States
Craig A. Spiegel, M.D.
🇺🇸
Bridgeton, Missouri, United States
Meridian Clinical Research
🇺🇸
Lincoln, Nebraska, United States
Boeson Research
🇺🇸
Missoula, Montana, United States
Corning Center for Clinical Research
🇺🇸
Horseheads, New York, United States
Dayton Clinical Research
🇺🇸
Dayton, Ohio, United States
Velocity Clinical Research
🇺🇸
Beachwood, Ohio, United States
Tribe Clinical Research
🇺🇸
Greenville, South Carolina, United States
Senders Pediatrics
🇺🇸
South Euclid, Ohio, United States
Lynn Institute of Tulsa
🇺🇸
Tulsa, Oklahoma, United States
Velocity Clinical Research Grants Pass
🇺🇸
Grants Pass, Oregon, United States
PanAmerican Clinical Research
🇺🇸
Brownsville, Texas, United States
WR - ClinSearch, LLC
🇺🇸
Chattanooga, Tennessee, United States
Bay Colony Pediatrics
🇺🇸
Dickinson, Texas, United States
South Texas Clinical Research
🇺🇸
Corpus Christi, Texas, United States
Mercury Clinical Research
🇺🇸
Houston, Texas, United States
Alliance for Multispecialty Research c/o Wee Care Pediatrics - Roy
🇺🇸
Roy, Utah, United States
Tekton Research
🇺🇸
San Antonio, Texas, United States
Mercury Clinical Research - Pediatric Center
🇺🇸
Richmond, Texas, United States
Alliance for Multispecialty Research
🇺🇸
Layton, Utah, United States
Clinical Research Partners, LLC
🇺🇸
Richmond, Virginia, United States
Centro de Atencion e Investigacion Medica S.A.S-CAIMED
🇨🇴
Puente Aranda, Bogota, Colombia
Clinica de la costa
🇨🇴
Barranquilla, Atlantico, Colombia
Fundacion Oftalmologica de Santander - FOSCAL
🇨🇴
Floridablanca, Santander, Colombia
PROBEBE en Hospital Universitario Maternidad Nuestra Senora de la Altagracia
🇩🇴
Santo Domingo, Distrito Nacional, Dominican Republic
Centro de Estudios en Infectologia Pediatrica S.A.S.CEIP
🇨🇴
Cali, Valle Del Cauca, Colombia
Registrum Group (Hospital Regional Marcelino Velez)
🇩🇴
Santo Domingo, Distrito Nacional, Dominican Republic
Registrum Group (Hospital Materno Infantil San Lorenzo de Los Mina)
🇩🇴
Santo Domingo, Distrito Nacional, Dominican Republic
MEDYVAC INTERNACIONAL SRL en Clinica Cruz Jiminian
🇩🇴
Santo Domingo, Distrito Nacional, Dominican Republic
SMI (Servicios Medicos Integrales)
🇬🇹
Guatemala, Guatemala
DEMEDICA
🇭🇳
San Pedro Sula, Cortés, Honduras
CECLISA
🇬🇹
Guatemala, Guatemala
Inverime S.A.
🇭🇳
Tegucigalpa, Francisco Morazan, Honduras
Investigacion Sin Limites
🇭🇳
Tegucigalpa, Francisco Morazan, Honduras
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
🇲🇽
Tlalpan, Ciudad De Mexico, Mexico
Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S.C.P.
🇲🇽
Mérida, Yucatan, Mexico
Panamerican Clinical Research Mexico S.A. de C.V. (Queretaro Site)
🇲🇽
Queretaro, Mexico
Manila Doctors Hospital
🇵🇭
Manila, Metro Manila, Philippines
FAICIC S. de R.L. de C.V.
🇲🇽
Veracruz, Mexico
University of the Philippines Manila - National Institutes of Health (NIH) - Institute of
🇵🇭
San Juan, Batangas, Philippines
University of the Philippines - Philippine General Hospital
🇵🇭
Manila, Metro Manila, Philippines
National Children's Hospital
🇵🇭
Quezon City, Metro Manila, Philippines
FEU-NRMF
🇵🇭
Quezon City, Metro Manila, Philippines
Medical Mission Group Hospital-Lucban and Southern Luzon State University
🇵🇭
Lucena, Quezon, Philippines
Soweto Clinical Trials Centre
🇿🇦
Johannesburg, Gauteng, South Africa
REIMED Riger Park
🇿🇦
Boksburg, Gauteng, South Africa
Setshaba Research Centre
🇿🇦
Ga-Tshwene, Gauteng, South Africa
Wits Vida- Chris Hani Baragwanath Hospital
🇿🇦
Soweto, Gauteng, South Africa
Limpopo Clinical Research Initiative
🇿🇦
Thabazimbi, Limpopo, South Africa
Be Part Yoluntu Centre - Paarl
🇿🇦
Paarl, Western Cape, South Africa
Tiervlei Trial Centre
🇿🇦
Bellville, Western Cape, South Africa
Wits Vida Nkanyezi Site- Rahima Moosa Mother and Child Hospital
🇿🇦
Johannesburg, Gauteng, South Africa
Hospital Universitario Severo Ochoa
🇪🇸
Leganés, Madrid, Spain
Hospital Universitario de Torrejon
🇪🇸
Torrejon de Ardoz, Madrid, Spain
Complejo Hospitalario Universitario de Santiago
🇪🇸
Santiago de Compostela, A Coruña, Spain
Stellenbosch University Worcester
🇿🇦
Worcester, Western Cape, South Africa
Lakeside Healthcare Research
🇬🇧
Corby, Northamptonshire, United Kingdom
Hospital Universitario 12 de Octubre
🇪🇸
Madrid, Spain
Be Well Clinical Studies, LLC
🇺🇸
Lincoln, Nebraska, United States
WiWits RHI - Shandukani Research Centre
🇿🇦
Johannesburg, Gauteng, South Africa
Ark Clinical Research
🇺🇸
Long Beach, California, United States

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts